Table 5.

Reasons for discontinuation of first-line treatment (cases where the drug was discontinued are shown; multi-answer question)

	Total, n (%)	Interferon β-1b	Interferon β-1a	Glatiramer acetate	Dimethyl fumarate	Peginterferon β-1a
Treatment failure* (total or partial)	10 (62.5)	3	2	2	2	1
SPMS conversion	3 (18.8)	2	0	0	1	0
Pregnancy/planned pregnancy/breastfeeding	1 (6.3)	0	0	0	1	0
Clinically significant skin lesions	1 (6.3)	1	0	0	0	0
Other reasons (different from SmPC)	2 (12.5)	0	0	1	1	0
All terminated therapies	16 (100)**	5	2	3	5	1

SmPC – Summary of Product Characteristics, SPMS – secondary progressive multiple sclerosis

^*Total failure was defined as lack of response to a full 12-month course of first-line treatment: 1) at least two moderate relapses (increase of 1-2 EDSS points) or one severe relapse after 6 months of treatment (increase of > 2 EDSS points) and 2) new lesions on MRI performed after month 12 (> 1 Gd+ lesion or > 2 T2 lesions); the two conditions must be met simultaneously. Partial failure was defined as the occurrence of only one of the above criteria.

^**The total numbers/percentages of terminated therapies do not add up because in one case termination of therapy was due to two reasons.